Govt to recast Insacog as Covid cases decline

The Indian government is considering restructuring Insacog, the consortium monitoring genomic variations in SARS-CoV-2, due to the decline in new Covid-19 cases and reduced testing frequency. Experts aim to determine whether to continue extensive sequencing or streamline it to fewer laboratories based on current needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GVuWKcm
via IFTTT

Read More

Yatharth Hospital to acquire 60% stake in Faridabad-based facility

Yatharth Hospital and Trauma Care Services has greenlit the acquisition of a 60% stake in a yet-to-be-operational 400-bed hospital in Faridabad valued at Rs 152 crore. This move, alongside acquiring a super speciality hospital in Model Town, Delhi, aims to bolster its presence in the Delhi-NCR region.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3utniv4
via IFTTT

Read More

SumeetSSG to invest Rs 1,600 cr in Maharashtra; bags emergency medical service project

Medical emergency service provider SumeetSSG will invest Rs 1,600 crore in Maharashtra to implement the MEMS 108 Ambulance Project, introducing advanced ambulance fleets with specialised medical equipment. The ten-year project, valued at Rs 14,000 crore, aims to enhance healthcare infrastructure and emergency response services across the state.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/982qPQt
via IFTTT

Read More

Biocon Biologics' Bengaluru unit classified as voluntary action indicated by USFDA

Biocon Biologics' drug substance facility in Bengaluru has been classified by the USFDA as voluntary action indicated after a cGMP inspection conducted in February 2024. The classification means that while some objections were noted, no regulatory action is recommended. The facility is responsible for supplying rh-Insulin drug substance to the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A8l4LIK
via IFTTT

Read More

Cipla Q2 hit by seasonal chill, but investors need not worry

Cipla's September-quarter performance saw a 5.6% increase in consolidated net sales and a 15% rise in net profit despite slow seasonal growth in the anti-infectives category. The company expects a resurgence in growth due to seasonal respiratory illnesses and plans to address supply challenges and facility remediations in upcoming quarters.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uPDmSRM
via IFTTT

Read More

Fortis Healthcare gets CCI nod to acquire additional stake in Agilus Diagnostics for Rs 1,780 cr

The Competition Commission of India (CCI) has approved Fortis Healthcare's acquisition of an additional 31.52% stake in Agilus Diagnostics, raising its total share to 89.2%. Additionally, CCI has greenlit the merger of Diliigent Power into DB Power and the reorganisation of Decore Thermal Power.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bQkLmIr
via IFTTT

Read More

Lyfius Pharma Penicillin-G plant inaugurated by PM Modi

Prime Minister Narendra Modi virtually inaugurated Lyfius Pharma's Penicillin-G plant in Kakinada, Andhra Pradesh, with a production capacity of 15,000 MT. The Rs 2,500 crore investment under the PLI Scheme aims to boost domestic manufacturing, reduce import dependency, and support 'Atmanirbhar Bharat' in establishing India as a global pharmaceutical hub.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zJ14kOU
via IFTTT

Read More

Govt asks manufacturers to cut price of 3 anti-cancer drugs

The government has directed manufacturers to lower prices of Trastuzumab, Osimertinib, and Durvalumab after exempting them from customs duty and reducing GST. This measure aims to ensure affordable anti-cancer drugs for consumers. Companies must update and report new prices to authorities and dealers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/L8xRb4u
via IFTTT

Read More

PM Modi to launch, inaugurate multiple health sector projects worth over Rs 12,850 cr today

On the occasion of Dhanvantari Jayanti and 9th Ayurveda Day, Prime Minister Narendra Modi will launch, inaugurate and lay the foundation stone of multiple projects related to the health sector worth around Rs 12,850 crore on Tuesday at the All India Institute of Ayurveda (AIIA) in the national capital.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9oFv5Ei
via IFTTT

Read More

Dr Reddy's launches medication to treat chronic constipation

Dr Reddy's Laboratories has launched BixiBat, a new drug for chronic constipation in India. It is the first company to receive approval from the CDSCO for Elobixibat. The drug works by increasing bile acid concentration in the colon, promoting bowel movements. Clinical studies showed promising results. Shares of the company went up by 0.84 percent.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bViqB0G
via IFTTT

Read More

NCIL developing indigenous dialysis machine in collaboration with NIT Silchar

Nephro Care India Limited, in collaboration with NIT, Silchar, is developing an AI-enabled smart haemodialysis machine with a grant from West Bengal's Department of Science and Technology. This prototype aims to slash costs by up to 75%, making renal care more affordable and accessible, especially in rural areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qiAbKfX
via IFTTT

Read More

Could a Rs 72 lakh drug cost just Rs 3,000? A 24-year-old's courtroom revelation

A 24-year-old SMA patient in Kerala High Court revealed that Risdiplam, a crucial SMA drug, could be locally produced for Rs 3,000 annually compared to the current Rs 72 lakh. Highlighting the need for local manufacturing, the petition challenges the sufficiency of the Indian Health Ministry's financial aid and crowdfunding efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x9huOws
via IFTTT

Read More

Piramal Pharma deploying USD 85 mn capex this fiscal: Nandini Piramal

Piramal Pharma is investing USD 85 million this fiscal for initiatives like capacity expansion and maintenance. They have already used USD 30 million in the first half. Part of the funds will be for domestic use and some for the US. The company aims to reach USD 2 billion in revenue by FY30.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ySeLq6I
via IFTTT

Read More

Big chase for a cancer drug: The urgent need for affordable Keytruda alternatives

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, Indian companies are developing more affordable versions. Efforts are also focused on expanding indications and improving financial access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qq2VPOL
via IFTTT

Read More

Abhay HealthTech acquires MNP Healthcare to expand footprint in OTC segment

Abhay HealthTech has acquired MNP Healthcare to expand its OTC consumer healthcare sector. The deal includes MNP's brands, products, people, and manufacturing facilities. MNP Healthcare's directors will join Abhay HealthTech's advisory board. This acquisition enhances Abhay HealthTech's portfolio in areas like rapid testing kits, hygiene, skincare, supplements, women and baby care, and children wellness.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ArwHT2D
via IFTTT

Read More

Calcium, Vitamin D3 tablets, 47 others fail CDSCO's quality check: Check if your medication is safe?

The Central Drugs Standard Control Organisation (CDSCO) identified 49 drugs failing quality tests in its September report. Among these are commonly prescribed antibiotics, supplements, and pain relievers. The report also flagged four products, including popular calcium and prostate treatments, as “spurious,” manufactured by unverified companies. CDSCO’s ongoing efforts, which involved sampling 3,000 drug batches in September alone, are aimed at minimizing non-standard drugs in the market, ensuring the safety of public health through rigorous monthly monitoring.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/e8En12y
via IFTTT

Read More

Why technology alone can't fix India’s big healthcare divide

India's healthcare gap can't be bridged by technology alone; infrastructure and human resources are essential. Rural areas face severe deficiencies in medical facilities and professionals. Affordability and awareness also present major challenges, requiring comprehensive investment and public health campaigns to address these deep-rooted issues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EHO6oPx
via IFTTT

Read More

Want glowing skin? Include these 5 drinks in your diet

Get a radiant, healthy glow by adding these five skin-loving drinks to your daily routine. From green tea to beet juice, each boosts hydration and revitalizes skin.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lT5mbIt
via IFTTT

Read More

Pharma bodies flag risks of refurbished medical gear imports

Medical device manufacturers are urging India's health minister to revoke the policy allowing unchecked import of refurbished medical devices like CT scanners and MRI machines. They argue this poses risks to patient safety and jeopardizes investments made under the Make in India initiative. They seek stricter regulations to ensure compliance with the National Medical Devices Policy 2023.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5DHFV8I
via IFTTT

Read More

Weight-loss drugs didn't curb health costs within two years, data show

U.S. health insurance claims analysis shows that two years after starting Novo Nordisk's Wegovy or similar GLP-1 drugs, annual medical costs for obese patients increased by 46% to $18,507, with no reduction in obesity-related medical events compared to a control group. These high costs concern employers and government officials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9WsZrNp
via IFTTT

Read More

Mankind Pharma completes Rs 13,768 cr BSV acquisition

Mankind Pharma has completed the acquisition of Bharat Serums and Vaccines Ltd for Rs 13,768 crore. This acquisition strengthens Mankind Pharma's position in the Indian women's health and fertility drug market. The transaction aligns with Mankind's strategy to access high entry barrier products and complex R&D platforms, promising accelerated growth and expanded market access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8TzXQpi
via IFTTT

Read More

McDonald's E. Coli outbreak: Symptoms, source, and when to get medical help

An E. coli outbreak linked to McDonald's Quarter Pounders has left one person dead and 49 others ill. Find out its symptoms, likely sources of contamination, and when to seek medical help.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QI19TLX
via IFTTT

Read More

Zydus Lifesciences gets WHO prequalification for Typhoid Vi conjugate vaccine

Zydus Lifesciences Ltd has received in-principle approval from the WHO for its Typhoid Vi conjugate vaccine, ZyVac TCV. Eligible for UN procurement, the vaccine targets 6-month to 65-year-olds and addresses high typhoid incidence in India, Africa, and Southeast Asia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LPqGtRs
via IFTTT

Read More

GST reduction will make insurance little affordable for customers, says Department of Finance Joint Secy

The Department of Finance's Joint Secretary stated that a reduction in Goods and Services Tax (GST) could make insurance more affordable for customers. Following requests for the removal of GST on term life and health insurance premiums, a Group of Ministers (GoM) met to discuss potential exemptions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ybhCFUe
via IFTTT

Read More

Manipal HealthMap acquires iGenetic Diagnostics

Manipal HealthMap has fully acquired Mumbai-based iGenetic Diagnostics to enhance its diagnostic services in key markets such as Maharashtra, Madhya Pradesh, and Karnataka. The acquisition aims to establish over 200 centers by 2027, contributing to a more integrated diagnostic services network across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/X6xgpTu
via IFTTT

Read More

8 eco-friendly tips to combat air pollution during Diwali

Diwali is a time of celebration, but it can also lead to increased air pollution. By adopting eco-friendly practices, we can enjoy the festivities while protecting our environment and health. Here are eight effective ways to combat air pollution this Diwali.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MKibS6Y
via IFTTT

Read More

Diabetes, cardiac drugs market grows over 3x in 10 years

India's cardiac and anti-diabetes drugs market has surged over threefold in the past decade, reaching ₹30,000 crore and ₹17,000 crore respectively. Innovative medicines and loss of patents have driven growth, with several brands now contributing significantly to market turnover.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VGmJgX1
via IFTTT

Read More

The ‘A’ and ‘B’ of diabetes: When less is more

HbA1c testing is crucial for diabetes management as it reflects average blood sugar levels over three months, unlike single-point fasting or postprandial tests. Regular testing and weight management can significantly reduce diabetes complications, yet many people in India neglect this vital check, exacerbating health risks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5vKZ3M2
via IFTTT

Read More

Alembic Pharma gets USFDA nod for generic hypertension treatment capsules

Alembic Pharmaceuticals has received USFDA final approval for its generic Diltiazem Hydrochloride extended-release capsules in strengths of 120 mg, 180 mg, and 240 mg to treat hypertension and chronic stable angina. These capsules are therapeutically equivalent to Allergan Sales LLC’s Dilacor XR, with an estimated market size of USD 28.2 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LRUItQN
via IFTTT

Read More

Indian pharma firms trail global peers in R&D, innovation, and talent metrics: FAST India-IIFL Securities

Indian pharmaceutical firms lag behind global companies in R&D intensity, PhD employee proportion, and patents and publications per billion USD revenue, the report said. Global firms produce significantly more patents and publications, it added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gAqY2wJ
via IFTTT

Read More

India's bioeconomy valued at $150 bn, innovation holds key to global leadership: BIRAC MD

India's biotechnology sector, valued at USD 150 billion, is expanding, yet innovation and product development potential remain untapped. BIRAC supports startup growth and R&D investment to elevate India's bioeconomy, though increased private-sector investment and streamlined regulatory processes are essential for global leadership in biotech.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5v48bkq
via IFTTT

Read More

GST on term life insurance premium, senior citizen's health coverage likely to be exempt

The Group of Ministers (GoM) is likely to recommend exempting Goods and Services Tax (GST) on term life insurance premiums and health insurance premiums paid by senior citizens. During a recent meeting, the GoM decided to exempt GST for health insurance coverage up to Rs 5 lakh for individuals (excluding seniors), while premiums above this threshold will still attract 18% GST. Currently, 18% GST applies to life insurance premiums as well.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZSewcEy
via IFTTT

Read More

7 common post-meal mistakes that can ruin your digestion

By being aware of these post-meal habits and making adjustments, you can support better digestion and enhance your overall health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zkXF35h
via IFTTT

Read More

Sparsh Hospitals lines up expansion plans

The Sparsh Group of Hospitals, led by Sharan Shivaraj Patil, plans to expand by investing ₹350-400 crore in two new Bengaluru hospitals and ₹150 crore in an R&D centre. They aim to raise equity funds in fiscal 2026. The company remains profitable and will add some debt for expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vCcwypE
via IFTTT

Read More

Stop believing these 6 nutritional myths: Get the facts!

Nutritional myths can often mislead us, making it difficult to make informed choices about our diets. Here are seven common nutritional myths that you should stop believing:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q1sN9BJ
via IFTTT

Read More

Alia Bhatt opens up about ADHD: Key insights & symptoms you should know

Alia Bhatt opens up about her ADHD journey, sharing how it affects her daily life and moments of peace. She discusses her diagnosis, common symptoms, and how it shapes her experiences on set and with her daughter.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0th9LrM
via IFTTT

Read More

NCLAT closes insolvency proceedings against JHL as Max Healthcare settles creditor's claims

The National Company Law Appellate Tribunal (NCLAT) has ended insolvency proceedings against Jaypee Healthcare, as financial creditors' dues were settled by Max Healthcare with a Rs 1,035.29 crore payment. The CIRP was initiated by NCLT following a petition by JC Flowers Asset Reconstruction Ltd.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3MacBfH
via IFTTT

Read More

Pleasure profits: Sex stimulants show enhanced performance

Sales of sex stimulants and rejuvenators in India have surged by 17% over the past year, with significant gains in sildenafil and tadalafil brands like Viagra and Cialis. This growth is attributed to decreased inhibitions and increased openness to sexual wellness, supported by accessible knowledge and healthcare professionals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rQaHV3i
via IFTTT

Read More

US, Europe key export destinations for drug formulations, biologicals, surgical goods

India’s exports of surgical goods, drug formulations, and biologicals are gaining ground in US and European markets. The sector has shown substantial growth during April-August 2024. Exports to the US, UK, and other countries highlight India as a prominent global supplier of high-quality pharmaceutical and surgical products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p6XGMbe
via IFTTT

Read More

Intermittent fasting: Who should avoid this popular eating pattern?

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OK56W3H
via IFTTT

Read More

Piyush Goyal holds meeting to address concerns of pharmaceutical exporters

Union Commerce Minister Piyush Goyal engaged with key pharmaceutical industry stakeholders, including the IMDA's General Secretary, to tackle challenges faced by pharmaceutical exporters and enhance India's position in the global market. The meeting highlighted collaborative efforts to address hurdles and maintain competitiveness in quality and pricing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DTUwWGv
via IFTTT

Read More

SeaLink, promoter plan to sell majority stake in Surya Hospital

Private equity firm SeaLink Capital Partners and the Surya Children's Medicare promoter plan to sell their stakes in western India's largest children's hospital chain. Valued at ₹1,000-1,200 crore, JM Financial is managing the process, targeting global PE firms and leading Indian hospital chains for the acquisition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SA4KlzD
via IFTTT

Read More

From Code to Care: How AI and hyperautomation can change patient care in India

Indian healthcare is being transformed by hyperautomation and other digital technologies. These advancements are improving patient care, reducing costs, and streamlining processes. Successful implementation requires collaboration between healthcare providers, government agencies, and tech companies. The shift towards digitisation is expected to overcome inefficiencies and create a more sustainable healthcare system for the future.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Km4h8vD
via IFTTT

Read More

Strides Pharma's OneSource raises Rs 801 crore in pre-listing round

OneSource Specialty Pharma, an associate of Strides Pharma, secured Rs. 801 crore from investors including HBM Healthcare Investments and WhiteOak Capital. With these funds, OneSource will reduce debt and enhance its manufacturing capabilities. The company aims to list its shares by March 2025 and targets being debt-free by FY26. Strides shareholders will benefit significantly from this transaction.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MIlZQHG
via IFTTT

Read More

Government seeks dismissal of plea on Covishield deaths, Supreme Court to hear on November 26

The Supreme Court is hearing a plea from parents demanding an investigation into their daughters' deaths allegedly caused by Covishield vaccine. The government argues vaccination was voluntary and widely affirmed. The parents accuse the government of misleading the public and insufficiently addressing adverse effects.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y681QIE
via IFTTT

Read More

Cipla, Alkem Laboratories in final lap to buy SMT

Promoters of SMT—the Kotadia family— plan to keep a minority stake after the transaction that would see other shareholders also divest their holdings. “They could retain about 15-20% stake post the deal,” said one of the persons cited above. Morgan Stanley PE Asia and Samara Capital collectively own 49% of SMT, while Kotak Pre-IPO Opportunities Fund has a 6% stake. The Kotadias own the remaining 45%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O743IdY
via IFTTT

Read More

Delhi HC allows Zydus Lifesciences to sell breast cancer drug Sigrima

The Delhi High Court division bench has allowed Zydus Lifesciences to sell its breast cancer drug Sigrima amidst accusations of it being similar to Roche's Perjeta. The court invalidated an earlier restraint order, noting no patent infringement by Zydus.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eTvDiMN
via IFTTT

Read More

Marengo Asia eyes rights issue, stake sale to fund growth

Marengo Asia Healthcare plans to expand its bed capacity to 3,000 by 2026 and may involve an external investor. The platform has acquired multiple hospitals and is exploring further acquisitions and asset-light operation contracts. Currently, it operates with a 1,700-bed capacity and aims to reach an EBITDA margin above 20% in the next 12 to 18 months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OBAsU2b
via IFTTT

Read More

Turmeric for weight loss: 5 easy ways to shed pounds naturally

Turmeric, a golden spice known for its anti-inflammatory and antioxidant properties, can be a helpful addition to your weight loss routine. Rich in curcumin, turmeric boosts metabolism, aids digestion, and helps detoxify the body. Here are five ways to incorporate turmeric into your daily routine for effective weight management:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XE6l8bs
via IFTTT

Read More

11 countries already recognise Indian pharmacopoeia as their standard: DCGI Rajeev Raghuvanshi

India is supplying drugs, vaccines, and medical devices to over 200 countries, with 11 countries recognizing Indian pharmacopoeia standards. The regulatory system is advanced, approving around 100 global clinical trials annually, and India's vaccine regulatory framework meets WHO global standards, bolstering its position as a significant international vaccine supplier.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dXGZcMU
via IFTTT

Read More

7 compelling reasons to add sweet potatoes to your diet

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8d3jB6O
via IFTTT

Read More

India reaffirmed its role as the pharmacy of the world during COVID: JP Nadda at International Conference of Drug Regulatory Authorities

Union Minister of Chemicals and Fertilisers JP Nadda, during his address at the 19th International Conference of Drug Regulatory Authorities (ICDRA), hailed India's crucial role during the Covid-19 pandemic and how the country is emerging as a global leader in health resilience and innovation, thereby reaffirming its position as the 'pharmacy of the world.'

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uVCrfJL
via IFTTT

Read More

More health packages focused on elderly care likely to be added to AB-PMJAY

The National Health Authority is set to extend the Ayushman Bharat scheme to include those aged 70 and above, benefiting around six crore citizens. The scheme will offer expanded health packages focusing on geriatric care and provide free treatment up to Rs 5 lakh annually.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9QOyAK3
via IFTTT

Read More

Glenmark arm recalls products in US for manufacturing issues

Glenmark Pharmaceuticals is recalling 45,504 bottles of Ryaltris Nasal Spray and 11,568 tubes of Ciclopirox Gel in the US due to manufacturing defects, including a clogged dip tube and broken tube seals. The USFDA has classified the recalls as Class II and Class III respectively.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/L0QbREr
via IFTTT

Read More

Star Health says it received $68k ransom demand after data leak

Star Health, India's largest health insurer, received a $68,000 ransom demand following a significant customer data leak. The hacker, using Telegram and a website, exposed sensitive information. The company has taken legal action and is cooperating with Indian cyber security authorities to identify the perpetrator.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RDM3cOY
via IFTTT

Read More

PE firms queue up for Novartis' Indian arm

The PE firms are up against Dr Reddy's, which has an alliance with Novartis for marketing some of its off-patent products and is also expected to bid. Alkem Labs is also in the fray. Novartis India has a market capitalisation of around ?2,500 crore though bids are likely to value it lower, as per those in the know. Non-binding bids are due later this month.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3dqzuBg
via IFTTT

Read More

India's top drug regulator meets WHO standards for functional vaccine regulatory system

A WHO-led team reviewed India's vaccine regulatory system from September 16 to 20. The system was declared functional by meeting WHO's global standards and benchmarks. India's regulatory system has retained maturity level 3 with top marks in several functions. This achievement highlights India's significant role in the global pharmaceutical industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oDfeaIQ
via IFTTT

Read More

No easy access for morning-after pill?

The government is considering a proposal requiring prescriptions for emergency contraception pills due to concerns about misuse and health risks. Experts argue that limiting access could result in more unwanted pregnancies, emphasizing the need for balanced information rather than restrictive measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NbQCxj8
via IFTTT

Read More

Zydus gets US nod for schizophrenia generic medicine

Zydus Lifesciences has received the USFDA's final approval to produce a generic version of Paliperidone extended-release tablets, which are used to treat schizophrenia and schizoaffective disorders. The approval covers strengths of 1.5 mg, 3 mg, 6 mg, and 9 mg, with production set at the SEZ facility in Ahmedabad.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DfHrg9w
via IFTTT

Read More

Rural households' out-of-pocket spend on hospitalisation stay Rs 4,129/yr, urban Rs 5,290: Govt Report

A government survey reported that the average out-of-pocket medical expenses for hospitalization over the past year were Rs 4,129 in rural areas and Rs 5,290 in urban areas. For non-hospitalization treatments in the last 30 days, the costs averaged Rs 539 in rural households and Rs 606 in urban ones.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rSTCspQ
via IFTTT

Read More

QR code must for all vaccines to check fakes

The Indian government has mandated QR codes on all vaccines to combat counterfeiting and ensure authenticity. The Drug Controller General of India indicated an aggressive campaign against non-compliance, supported by strict enforcement and prosecution measures. Future expansions include QR code implementation on more products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cGsxv9R
via IFTTT

Read More

Govt waives testing of cough syrups for export to key markets

India has waived off mandatory testing of cough syrups for export to countries like USA, UK, and EU if their regulatory authorities have approved the manufacturing plants. This change follows earlier requirements due to contamination concerns in Gambia and Uzbekistan. The Directorate General of Foreign Trade updated the export policy to reflect this exemption for specific approvals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aTiEJl7
via IFTTT

Read More

Aurigene reports promising phase-1 data for its CAR-T therapy against myeloma

Aurigene Oncology has announced promising phase-1 results for its novel CAR-T cell therapy, Ribrecabtagene autoleucel, in patients with multiple myeloma. All patients achieved clinical response, with no high-grade safety events reported. The Indian drug regulator has approved the commencement of a phase-2 trial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Hhc72ZO
via IFTTT

Read More

Are you making these 5 common fitness mistakes?

By being mindful of these common mistakes, you can enhance your fitness routine and work towards achieving your health goals more effectively.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hERP7Ys
via IFTTT

Read More

Ayushman Bharat to expand coverage for elderly healthcare to include Alzheimer's, Cancer, and more

Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) will expand to cover treatments for conditions like Alzheimer's, dementia, heart failure, and cancer in the elderly. This move aims to help six crore senior citizens, offering crucial healthcare access. A committee of medical experts is developing new packages to address these needs effectively.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mR6rBJA
via IFTTT

Read More

7 flavorful foods rich in healthy fats for a healthier you

Here are seven foods packed with healthy fats that can enhance your diet:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hTOampW
via IFTTT

Read More

Garmin, Apollo Hospitals join hands for health monitoring & wellness

Garmin and Apollo HealthAxis have partnered to bring advanced fitness tracking and personalized wellness programs to India. Garmin fitness trackers will be integrated with Apollo Health Plans, offering health monitoring and AI-powered health prediction. The collaboration also aims to improve healthcare in rural areas by combining Garmin's technology with Apollo's expertise.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qCc7tVU
via IFTTT

Read More

Pharma companies seek more teeth for agencies to fight fakes

India's leading drug makers, through the Indian Pharmaceutical Alliance, have petitioned the Supreme Court to enable police and drug inspectors to investigate and prosecute counterfeit drug manufacturers. They argue that without proper enforcement and protection, the prevalence of counterfeit drugs has increased, affecting public health and India's global pharmaceutical reputation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aIjZTn7
via IFTTT

Read More

What lifestyle changes can help you stay cancer-free?

By adopting a healthier lifestyle and being proactive about your health, you can make a meaningful impact on your overall well-being.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/joznMk1
via IFTTT

Read More

ICMR to study efficacy of Metformin, Inositol in PCOS treatment

India's ICMR will study the efficacy of Metformin and Inositol drugs in improving fertility and birth outcomes in PCOS women. Despite widespread use, evidence on their effectiveness is limited, especially in the Indian context. The multi-centre study will address this knowledge gap.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1fchZ23
via IFTTT

Read More

Detox dangers: Why you should reconsider

Detoxes lack scientific backing and may be unsafe due to poor regulation. Experts recommend consulting a healthcare professional for personalized, sustainable health solutions instead of relying on detox products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8KVyroN
via IFTTT

Read More

Govt may mandate QR codes to check fake cancer drugs

The Indian government plans to require QR codes on all cancer drugs. This step aims to prevent counterfeit medicines and ensure drug authenticity. The Drugs Technical Advisory Board has agreed to the proposal. An amendment to the Drugs Rules, 1945, is necessary before implementation. This move follows earlier efforts to add barcodes on top 300 drug brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Zzn8X2y
via IFTTT

Read More

Lupin subsidiary acquires 9 brands South African firm

Lupin's subsidiary, in partnership with ImpiloVest, has acquired nine brands from MNI in South Africa, enhancing its portfolio in complementary and alternative medicines. The acquired brands address various health issues, aligning with Lupin's commitment to holistic and sustainable healthcare solutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/o6Pi3Za
via IFTTT

Read More

Quick access to key HIV drug hinges on waiver of local clinical trials: Experts

Faster access to HIV drug lenacapavir in India hinges on the waiver of local clinical trials. Six companies, including three from India, have non-exclusive, royalty-free licenses to produce generic versions. They must apply for waivers to supply the drug locally and in 120 low- and middle-income countries. Approval from the drug regulator is crucial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/35L7eW2
via IFTTT

Read More

Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug Lenacapavir

Emcure Pharmaceuticals has partnered with Gilead Sciences Ireland UC to manufacture and distribute generic lenacapavir for HIV prevention and treatment. This royalty-free agreement focuses on increasing access to the drug in 120 countries, especially resource-limited nations. Emcure aims to provide high-quality, low-cost HIV medication to improve health outcomes globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0jB2cKg
via IFTTT

Read More

CCI clears Rs 13,630 cr Mankind Pharma acquisition of Bharat Serums

The Competition Commission of India (CCI) has approved Mankind Pharma's ₹13,630-crore acquisition of Bharat Serums and Vaccines. This acquisition will strengthen Mankind's position in the Indian women's health and fertility drug market. Mankind Pharma and Bharat Serums both specialize in pharmaceutical formulations and healthcare products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WZEcsIU
via IFTTT

Read More

Dr Reddy's enters voluntary licensing deal with Gilead for long-acting HIV drug

Dr. Reddy’s has partnered with Gilead Sciences to manufacture and market the HIV drug Lenacapavir in India and 120 other countries. The agreement includes developing Lenacapavir for both treatment and potential prevention of HIV. This collaboration aims to make this advanced treatment accessible in regions with high HIV burdens.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HZbqXu5
via IFTTT

Read More

CCI clears Rs 13,630-cr Mankind Pharma-Bharat Serums Vaccines deal

The Competition Commission of India has approved Mankind Pharma's Rs 13,630 crore acquisition of Bharat Serums and Vaccines. This acquisition, which includes a 100% stake, advances Mankind Pharma's position in the women's health and fertility drug market and grants access to critical care products with established R&D platforms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bRyXsdU
via IFTTT

Read More

Government looking to tweak regulatory norms for MedTech, pharma sectors: Niti Aayog's VK Paul

The Indian government is considering regulatory revisions for the MedTech and pharma sectors and has sought input from the industry. Niti Aayog member VK Paul highlighted the need to update the regulatory framework to support advancements in medical technology and pharma, aiming for enhanced exports and innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QyVP3OY
via IFTTT

Read More